Prostaglandin E1. A new therapy for refractory right heart failure and pulmonary hypertension after mitral valve replacement.

[1]  J. Halperin,et al.  Nitroglycerin therapy in the management of pulmonary hypertensive disorders. , 1984, The American journal of medicine.

[2]  C. Wildevuur,et al.  The effect of prostaglandin E1 in patients undergoing clinical cardiopulmonary bypass. , 1983, The Annals of thoracic surgery.

[3]  W. Zapol,et al.  Thromboxane mediates acute pulmonary hypertension in sheep extracorporeal perfusion. , 1982, The American journal of physiology.

[4]  B. Massie,et al.  Deleterious effects of hydralazine in patients with pulmonary hypertension. , 1982, The New England journal of medicine.

[5]  J. Shinn,et al.  Pulmonary artery balloon counterpulsation for acute right ventricular failure. , 1980, The Journal of thoracic and cardiovascular surgery.

[6]  J. Dubiel,et al.  Effects of prostaglandin E1 on pulmonary circulation in patients with pulmonary hypertension. , 1978, British heart journal.

[7]  R. Colman,et al.  Prostaglandin E1 inhibitis platelet aggregation by a pathway independent of adenosine 3',5'-monophosphate. , 1978, Science.

[8]  J. Demeules,et al.  Ineffectiveness of methylprednisolone in the treatment of pulmonary dysfunction after cardiopulmonary bypass. , 1975, American journal of surgery.

[9]  R. Bartlett,et al.  Prolonged extracorporeal cardiopulmonary support in man. , 1974, The Journal of thoracic and cardiovascular surgery.

[10]  J. R. McCurdy,et al.  Cardiovascular effects of prostaglandin E1. , 1967, The Journal of pharmacology and experimental therapeutics.

[11]  J. Mead,et al.  Prostaglandins, Thromboxanes, and Prostacyclin , 1986 .